Patients
This is a secondary analysis of a prospective study performed in PTB32W.
From November 2017 to April 2020, every PTB32W admitted to the NICU at
Hospital Puerta del Mar in Cádiz, Spain (inborn or transferred from
another hospital in the first 24 hours of life) was recruited with
parental consent. Infants with chromosomal abnormalities, major
malformations or those who died before 36 weeks’ PMA were excluded. The
local Ethics Committee approved the study protocol, with the internal
number LUS-NEO-17-01. We selected the patients that received diuretics
before 36 weeks’ PMA, and had more than one LU before and after
beginning of treatment. Diuretics recorded were furosemide,
hydrochlorothiazide and spironolactone. Diuretics were prescribed by the
attending neonatologist, who was not aware of the LU results.